Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 9/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | ARG2 | P78540 | 5/20 | 0.33 |
| ▸ | ARG1 | P05089 | 4/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349849 | 1.00 | GGT1 (0.53) | GGT1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL17378062 | 0.83 | KDM4E (0.54) | GGT1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL900182 | 0.83 | KDM4E (0.54) | GGT1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL900178 | 0.83 | KDM4E (0.54) | GGT1KDM4EMAPTTHRBALOX15 | |
| Hydrochloric Acid SCHEMBL16993797 | 0.81 | KDM4E (0.52) | GGT1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL7259702 | 0.79 | KDM4E (0.50) | GGT1KDM4EMAPTTHRBALOX15 | |
| Ethylene SCHEMBL28132201 | 0.79 | KDM4E (0.50) | GGT1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL313273 | 0.77 | MAPT (0.48) | GGT1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL3137754 | 0.77 | MAPT (0.48) | GGT1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL1157604 | 0.77 | MAPT (0.48) | GGT1KDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779634-B2 | Fungal iron acquisition inhibitors and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-10-10 | — | — | US | claimed |
| US-20220211820-A1 | FUNGAL IRON ACQUISITION INHIBITORS AND USES THEREOF | UNIV CASE WESTERN RESERVE (US) | 2022-07-07 | — | — | US | claimed |
| US-11229685-B2 | Fungal iron acquisition inhibitors and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-01-25 | — | — | US | claimed |
| US-20150366948-A1 | FUNGAL IRON ACQUISITION INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2015-12-24 | — | — | US | claimed |
| US-8829004-B2 | Method for inducing tumor apoptosis by increasing nitric oxide levels | UNIVERSITAETSKLINIKUM FREIBURG (DE) | 2014-09-09 | — | — | US | claimed |
| WO-2014120774-A1 | FUNGAL IRON ACQUISITION INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-08-07 | — | — | WO | claimed |
| EP-2056827-B1 | METHOD FOR INDUCING TUMOR APOPTOSIS BY INCREASING NITRIC OXIDE LEVELS | UNIVERSITAETSKLINIKUM FREIBURG (DE) | 2013-12-25 | — | — | EP | claimed |
| US-20130059861-A1 | METHOD FOR INDUCING TUMOR APOPTOSIS BY INCREASING NITRIC OXIDE LEVELS | Universitätsklinikum Freiburg (DE) | 2013-03-07 | — | — | US | claimed |
| US-20090264398-A1 | METHOD FOR INDUCING TUMOR APOPTOSIS BY INCREASING NITRIC OXIDE LEVELS | UNIVERSITATSKLINIKUM FREIBURG (DE) | 2009-10-22 | — | — | US | claimed |
| EP-2056827-A1 | METHOD FOR INDUCING TUMOR APOPTOSIS BY INCREASING NITRIC OXIDE LEVELS | Universitätsklinikum Freiburg (DE) | 2009-05-13 | — | — | EP | claimed |
| WO-2008071242-A1 | METHOD FOR INDUCING TUMOR APOPTOSIS BY INCREASING NITRIC OXIDE LEVELS | Universitätsklinikum Freiburg (DE) | 2008-06-19 | — | — | WO | claimed |
| EP-1895012-A1 | Method for inducing tumor apoptosis by increasing nitric oxide levels | Universitätsklinikum Freiburg (DE) | 2008-03-05 | — | — | EP | claimed |
| EP-4087583-B1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-3810615-B1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-3897622-B1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12240867-B2 | Arginase inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-03-04 | — | — | US | disclosed |
| US-20080021097-A1 | Arginase levels/activity | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2008-01-24 | — | — | US | disclosed |
| WO-2007120709-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF LESIONED SITES OF BODY VESSELS | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070243224-A1 | Methods and compositions for treatment of lesioned sites of body vessels | ADVANCED CARDIOVASCULAR SYSTEMS, INC. | 2007-10-18 | — | — | US | disclosed |
| WO-2007111626-A2 | ARGINASE II: A TARGET FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229685-B2 | Fungal iron acquisition inhibitors and uses thereof | SLC40A1, SLC30A6, SLC30A7 | GGT1 1135/4885KDM4E 2245/4885MAPT 1759/4885 |
| US-12240867-B2 | Arginase inhibitors and methods of use | ARG1, ARG2, PRMT1 | GGT1 339/4885KDM4E 3207/4885MAPT 4174/4885 |
| US-20220211820-A1 | FUNGAL IRON ACQUISITION INHIBITORS AND USES THEREOF | SLC40A1, SLC30A6, SLC30A7 | GGT1 1135/4885KDM4E 2245/4885MAPT 1759/4885 |
| US-20080021097-A1 | Arginase levels/activity | ARG1, ARG2, MPO | GGT1 318/4885KDM4E 1893/4885MAPT 3564/4885 |
| US-11779634-B2 | Fungal iron acquisition inhibitors and uses thereof | SLC40A1, SLC30A6, SLC30A7 | GGT1 1135/4885KDM4E 2245/4885MAPT 1759/4885 |
| US-20150366948-A1 | FUNGAL IRON ACQUISITION INHIBITORS AND USES THEREOF | SLC40A1, SLC30A6, SLC30A7 | GGT1 1135/4885KDM4E 2245/4885MAPT 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.